Recent Updates
Recently added Catalysts
KYMR

Kymera Therapeutics Presents Late-Breaking Preclinical Data on IRAK4 Degrader KT-474 at IMMUNOLOGY2021™ Annual Meeting

Monday, May 10, 2021 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Kymera Therapeutics Presents Late-Breaking Preclinical Data on IRAK4 Degrader KT-474 at IMMUNOLOGY2021™ Annual Meeting

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+111%
120-day peak, hindsight
Typical move
4.3%
average across 7 past catalysts
Cash runway
~83 mo
Minimal dilution risk
Lead asset
KT-621
Phase 2 · Atopic Dermatitis

Full Press Release Details

Kymera Therapeutics Presents Late-Breaking Preclinical Data on IRAK4 Degrader KT-474 at IMMUNOLOGY2021™ Annual Meeting.
ShareAdd on Google
Tags: KYMR Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: May 10, 2021

Biotech snapshot

Cash runway
$1505M liquidity · $18M/mo burn
~83 mo
Minimal dilution risk
Lead asset
KT-621Phase 2
Atopic Dermatitis →

Catalyst track record

+111%
best trade around KYMR's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for KYMR.

See every catalyst's timing & PoA →